Leadership

Dr. Andrew (Drew) Otoo talks about how pharma employees can elevate their own value propositions.

Open communication gives people the opportunity to explore.

Dr. Amy P. Abernethy talks about her career moves from academia to industry to the US Food & Drug Administation.

Rajit Kamal, Vice President, Asia Pacific for DePuy Synthes, a Johnson & Johnson company, offers recommendations for those wishing to secure an expatriate assignment with their company.

Military veterans exemplify traits valuable to pharma industry.

COVID-19 creates a unique chance to refocus STEM strategies.

Creating stronger relationships can set off a chain of success.

Pharma requires leaders who are "polymaths" — that is, those with the breadth and depth of experience within each of the sub-functions of commercial operations. Niti Sawhney reports.

The need to prioritize digital skill-building companywide.

A look at the leadership themes that have resonated most in 2020.

How the pandemic helped prove a point.

In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Percival Barretto-Ko, President of Astellas Pharma, US, speaks to Michael Wong about why value and innovation are the top two focus areas to add to resumes in 2020.

Fiona Huzarski outlines four key recruitment lessons that pharma can take from the coronavirus crisis and use to move forward and thrive.

To effectively lead in today’s unpredictable environment, several major pharma companies are turning to a neuroscience-based learning approach to leadership development.

Creating behavioral change in the pharma workplace.

A look at how internship programs in the pharma industry have changed since the start of the COVID-19 pandemic.

Collaboratives, company initiatives address systemic barriers.

A look into the traits that hiring managers of pharma companies should be searching for when hiring for a leadership role.

Dr. Geeta Vemuri, founder of biopharma investment firm Agent Capital, talks about sustaining a career in the venture capital sector.

How COVID-19 has changed high-level recruitment.

Balancing bold and pragmatic approaches during times of crisis.

Examining today’s go-to options in landing a successful CFO as role evolves.

Every major pharma company undertakes some form of diversity and inclusion work. However, that doesn’t mean it’s reaching the decision-makers, writes Stephen Frost.

Recognizing that diversity and inclusion is no longer simply a “nice to have,” pharma has boosted efforts in this areas. But just how far are new industry initiatives moving the needle on D&I?

Diversity and inclusion shouldn’t be something that companies have to work hard at, writes Chris Coe.